Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrafy Life SciencesASX:VFY -0.71%5 EBITDA Margin % is -104,622.22% as of Dec. 2025. GuruFocus rates ASX:VFY with a GF Score™ of 5/100. The stock has 5 warning signs investors should review. Among 2,824 Software companies, Vitrafy Life Sciences ranks worse than 99.33% on this metric.
Vitrafy Life Sciences (ASX:VFY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vitrafy Life Sciences EBITDA Margin % Related Terms
Vitrafy Life Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vitrafy Life Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VFY vs MSFT, ORCL, PLTR: EBITDA Margin % Comparison
For the Software - Infrastructure subindustry, Vitrafy Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrafy Life Sciences EBITDA Margin % vs Software Industry
For the Software industry and Technology sector, Vitrafy Life Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vitrafy Life Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrafy Life Sciences (ASX:VFY) has a EBITDA Margin % of -104,622.22% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vitrafy Life Sciences and its competitors. According to the industry distribution chart, Vitrafy Life Sciences ranks #2805 out of 2824 companies in the Software industry, placing it in the top 99.3%.
Is Vitrafy Life Sciences' EBITDA Margin % too high?
Vitrafy Life Sciences' current EBITDA Margin % is -104,622.22%. Based on the distribution chart, Vitrafy Life Sciences ranks #2805 out of 2824 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vitrafy Life Sciences has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Vitrafy Life Sciences' EBITDA Margin % compare to MSFT and ORCL?
According to the Software industry distribution chart, Vitrafy Life Sciences ranks #2805 out of 2824 companies for EBITDA Margin %. This places Vitrafy Life Sciences in the lower half of its industry. The industry median EBITDA Margin % is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Software company?
The median EBITDA Margin % among Software companies is 8.10, based on 2,824 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vitrafy Life Sciences and its competitors. For the Software industry, the median EBITDA Margin % is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrafy Life Sciences's current EBITDA Margin % is -104,622.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrafy Life Sciences stock overvalued right now?
Vitrafy Life Sciences (ASX:VFY) has a current EBITDA Margin % of -104,622.22%. The current EBITDA Margin % is -104,622.22%. Vitrafy Life Sciences' overall GF Score™ is 5/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vitrafy Life Sciences (ASX:VFY), the current EBITDA Margin % is -104,622.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitrafy Life Sciences Ltd developed a range of proprietary smart cryopreservation hardware devices and Lifechain, an integrated, cloud-based software platform, to provide a complete, vertically integrated cryopreservation solution to retain the quality of cryopreserved biomaterials. The company devices includes Vitrafy's Smart Cryopreservation Device; Vitrafy's Smart Thawing Device and Vitrafy's Smart Packaging.
5GF Score
Get the complete analysis for ASX:VFY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VFY has been successfully added to your 
